 |
年间契约型资讯服务
商品编码
1876162
创造新机会：双特异性/多特异性药物市场Unlocking Opportunity: Dominate the Bi/Multispecific Drug Market with Confidence |
||||||
双特异性/多特异性药物正在革新癌症治疗，开启精准治疗、免疫活化和治疗潜力的新篇章。然而，在快速发展、激烈竞争和不断扩充的研发管线中，保持领先地位需要的不仅是洞察力，更需要前沿知识、策略远见和数据驱动的决策。
仅在2024/25年度，肿瘤药物研发管线就将迎来创新浪潮，届时将有278种新型双特异性/多特异性药物、超过800种事件驱动型药物、8566个事件以及2120个药物项目——这清晰地表明了该领域发展速度的加快和復杂性的增加。
隆重推出“肿瘤双特异性/多特异性药物分析工具”，这是一个全面的解决方案，旨在帮助您驾驭这一充满活力的领域，追踪新兴趋势，并把握突破性机会。
探索该领域的终极工具：
- 双标靶/多标靶疗法：以前所未有的方式克服肿瘤异质性和抗药性
- 下一代药物设计：蛋白质工程、免疫调节和检查点标靶的创新正在重塑癌症治疗
- 个人化医疗的未来：双标靶/多标靶疗法正在推动向个人化精准癌症治疗的转变
- 前所未有的市场成长：随着研发管线的快速扩张，现在正是投资变革性肿瘤解决方案的最佳时机
影响是什么？快速扩张的临床研发管线、突破性的FDA批准以及投资机会的激增，使双标靶/多标靶疗法领域成为当今癌症治疗领域最令人兴奋的前沿领域之一。
六大突破性优势：
"肿瘤双特异性/多特异性药物分析工具" 的功能
- 竞争格局追踪 - 监测活跃的机构、新药、目标分子和技术
- 加速许可和合作 - 接触领先的生物技术开发商、业务拓展和许可联繫人以及学术项目
- 增强高影响力报告和演示 - 利用近乎即时的市场情报支援数据驱动的决策。将所有资料汇出为预置的图表和表格。
- 与关键意见领袖 (KOL) 互动 - 与领先的临床和科学专家建立联繫。
- 寻找合适的投资者 - 利用我们专注于肿瘤领域的融资伙伴网络。
- 掌握产业动态 - 分析全球主要肿瘤学会议（AACR、ASCO、ESMO、ASH 等）的资料。
我们的肿瘤双标靶和多标靶分析工具透过持续更新和每月电子邮件提醒来保持最新状态。
触手可及数千种药物、标靶、公司、临床试验、交易等资讯。
支持与灵感
将我们的专业知识转化为您的虚拟业务拓展团队。我们提供全天候 (24/7) 支持，并透过我们丰富的操作指南影片库提供经过验证的最佳实践。从竞争对手产品线分析到用户提交的真实案例研究，您将找到可操作的见解来改进您的工作。
与您共同成长的工具：
与仅提供时间快照的静态报告不同，我们的分析工具提供一年的线上存取权限，包括近乎即时的更新、新功能、产品线提醒和专属支援。当您想要更进一步时，可以无缝续订您的访问权限或升级到 1stOncology，我们行业领先的全方位服务平台——您在癌症药物研发领域的全面合作伙伴。
系统需求：
- 基于 Web 的应用程序，与主流浏览器（Chrome、Firefox、Safari、Internet Explorer）
- 需要网路连接
取得无与伦比的智慧讯息，助力肿瘤药物研发的策略决策
该工具由屡获殊荣的人工智慧 (AI) 增强型智慧平台提供支援，该平台拥有超过 25 年的肿瘤学专业知识，可在肿瘤药物研发的各个阶段提供无与伦比的全面业务、竞争和临床智慧资讯。
在业务拓展和发现/评估方面，它提供了对全球肿瘤领域无与伦比的洞察力，涵盖从技术、靶点和新创公司到製药公司、学术和商业机会，并作为一个强大的交易资料库，整合了许可资讯和数千笔历史交易。
在临床开发方面，我们拥有业界领先的超过3000种生物标记情报库，追踪它们作为分层、预测和药效学标记物的作用，同时涵盖从早期到获批的伴随诊断工作。我们独特的早期成功/失败指标清晰地突出了临床开发领域的领先者和落后者，使我们能够监测和预测不断变化的环境。
我们的临床试验情报不仅限于终点，还涵盖给药细节、抗药性机制、不良事件、食物影响、试验阶段和进展、首次人体试验 (FIH)、肿瘤分期/分级和治疗线 (LoT)，从而提供试验格局的全面视图。
我们简化了联合疗法开发的复杂性，将标靶、药物模式、适应症和试验阶段分解，建构出不断演进的策略图谱，从而实现快速的策略决策。
最后，我们将真实世界数据 (RWE) 与针对每个开发阶段量身定制的多方面分析相结合。我们的工具涵盖所有区隔领域——药物模式、联合用药概况、生物标记集群——能够提供深入的背景信息，从而推动肿瘤研发领域更快、更智能、更循证的决策。
肿瘤生物製剂/多标靶药物分析工具覆盖范围区隔
| 竞争对手概览 | |
|---|---|
| 监测机构数量： | 超过 870 家 |
| 机构类型： 企业 私人 公立 学术机构 新创公司 癌症中心/医院 大型製药/生物技术 |
743 435 248 89 90 38 34 |
五大药物研发公司： |
|
排名前五的国家： |
|
| 研发管线 | |
|---|---|
| 药物总数： 发现 临床前 I期 II期 III期 商业化 标靶： 肿瘤类型： 临床试验： 临床生物标记： 合併用药 疗法： |
1,400+ 420+ 1,130+ 300+ 200+ 23 21 481 167 1,481 464 481 167 1,481 464 197 |
| 合作伙伴与联盟 | |
|---|---|
| 过去 5 年的合约数量： BD&L;合约： 全球学术 商业机会： |
350 超过1800 17 |
| 资金与投资者 | |
|---|---|
| 资金（过去5年）： 主要投资者： |
1100+ 231 |
The world of bi- and multispecific drugs is transforming cancer treatment, unlocking new levels of precision, immune activation, and therapeutic potential. However, with rapid advancements, fierce competition, and an ever-expanding pipeline, staying ahead requires more than just insights - it demands up-to-date intelligence, strategic foresight, and data-driven decision-making.
In 2024/25 alone, the oncology pipeline saw a surge of innovation, with 278 new bi/multispecific drugs, over 800 drugs with events, and 8,566 total events spanning 2,120 total drug programs - a clear signal of the accelerating pace and complexity in this space.
Introducing the Bi/Multispecific Drugs in Oncology Analytical Tool - your comprehensive solution to navigate this dynamic field, track emerging trends, and capitalize on groundbreaking opportunities.
The Ultimate Tool for Exploring What Makes This Field So Exciting:
- Dual & Multi-Targeting for Unmatched Precision: Overcome tumor heterogeneity and resistance like never before.
- Next-Gen Drug Engineering: Innovations in protein engineering, immune modulation, and checkpoint targeting are reshaping oncology.
- The Future of Personalized Medicine: Bi/multispecific drugs are leading the shift towards tailored, precision-based cancer therapies.
- Unprecedented Market Growth: With a rapidly expanding pipeline, now is the time to invest in transformative oncology solutions.
The impact? A rapidly growing clinical pipeline, breakthrough FDA approvals, and a surge in investment opportunities - making the bi/multispecific field one of the most exciting frontiers in oncology today.
6 Game-Changing Benefits for You:
With the Bi/Multispecific Drugs in Oncology Analytical Tool you will:
- Track the Competitive Landscape - monitor active organizations, new drugs, targets, and technologies
- Accelerate Licensing & Partnerships - access top biotech developers, BD&L contacts, and academic projects
- Power High-Impact Reports & Presentations - fuel data-driven decisions with near real-time market intelligence - all exportable in ready made graphs and tables.
- Engage Key Opinion Leaders (KOLs) - connect with clinical and scientific experts shaping the field
- Find the Right Investors - tap into a network of oncology-focused funding partners
- Stay Ahead of Industry Events - analyze data from top global oncology conferences (AACR, ASCO, ESMO, ASH, and more)
Your Bi/Multispecifics in Oncology Analytical Tool is never out of date thanks to continuous updates and monthly email alerts highlighting the latest developments in the field.
You will have thousands of drugs, targets, companies, clinical trials, deals and much more at your fingertips. See below for a breakdown of our near real-time coverage.
Support & Inspiration at Your Fingertips:
Leverage our expertise as your virtual business development team-ready when you are. Our 24/7 support ensures help is always available, while our rich library of How-to Training Videos empowers you with proven best practices. From competitive pipeline analysis to real-world case studies submitted by fellow users, you'll find actionable insights designed to elevate your work.
A Tool That Grows With You:
Unlike static reports that offer just a snapshot in time, our Analytical Tools provide a full year of online access-complete with near real time updates, new features, pipeline alerts, and dedicated support. When you're ready to go further, you can seamlessly renew your access or upgrade to our industry-leading full-service platform: 1stOncology-your comprehensive partner in oncology drug development.
System Requirements:
- Web-based application compatible with all major browsers: Chrome, Firefox, Safari, and Internet Explorer
- Internet access
Secure Your Access to Unrivaled Intelligence for Strategic Decision-Making in Oncology Drug Development
This tool is powered by an award-winning, artificial intelligence (AI) enhanced intelligence platform with over 25 years of expertise in oncology, delivering uniquely comprehensive business, competitive and clinical intelligence across all stages of oncology drug development.
For business development and search & evaluation, it provides unmatched visibility into the global oncology landscape - spanning technologies, targets, start-ups to pharma, and academic-commercial opportunities - making it a powerful deal book with integrated licensing contacts and thousands of past deals.
In clinical development, the tool features an industry-leading biomarker intelligence panel of over 3,000 biomarkers and tracks their roles as stratifying, predictive, and pharmacodynamic markers, alongside companion diagnostic initiatives from early stage to approval. Proprietary early success/failure indicators spotlight clinical leaders and laggards, helping you monitor and and anticipate shifts in the evolving landscape.
Our clinical trial intelligence goes beyond endpoints, capturing dosage details, resistance mechanisms, adverse events, food effects, trial phase and status progression, first-in-human (FIH) studies, tumor stage/grade, and line of therapy (LoT) - offering a complete view of the trial landscape.
We simplify the complexity of combination therapy development, breaking down targets, drug modalities, indications, and trial stages to create a map of evolving strategies for fast, strategic decision-making.
Finally, we integrate Real-World Evidence (RWE) with multi-point analytics tailored to any development stage. Whether segmented by drug modality, co-medication profiles, or biomarker clusters, the tool enables deep, contextual insights - driving faster, smarter, and evidence-based decisions in oncology research and development.
Coverage Breakdown from your Bi/Multispecific Drugs in Oncology Analytical Tool
| Competitor Overview | |
|---|---|
| Organizations Monitored: | 870+ |
|
Organization Types: Corporate Private Public Academic Startup Cancer Ctr/Hospital Big Pharma/Biotech |
743 435 248 89 90 38 34 |
Top 5 Drug Developers: |
|
Top 5 Nations: |
|
| Pipeline | |
|---|---|
|
Total No Drugs: Discovery Preclinical Phase 1 Phase 2 Phase 3 Marketed Targets: Tumor Types: Clinical Trials: Clinical Biomarkers: Drugs in Combination Therapies: |
1,400+ 420+ 1,130+ 300+ 200+ 23 21 481 167 1,481 464 197 |
| Deals & Alliances | |
|---|---|
|
No. Deals (Last 5 Years): BD&L Contacts: World-Wide Academic Commercial Opportunity Projects: |
350 >1,800 17 |
| Funding & Investors | |
|---|---|
|
Funding (Last 5 Years): Top Investors: |
>1,100 231 |
